Data from the BRIDGES study suggest that protein truncating variants in BRCA2 and PALB2 are associated with a 17–22% and 11–13% absolute risk of developing low and high-grade ER + HER2- breast cancer, respectively, and a 7–9% lifetime risk of developing TNBC by age 80. Here, PALB2 is linked to breast carcinoma.